Moneycontrol PRO
Open App

Hold Glenmark Pharmaceuticals; target of Rs 440: ICICI Direct

ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 440 in its research report dated August 16, 2022.

August 17, 2022 / 03:19 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Glenmark Pharmaceuticals

Glenmark’s business is separated into three entities – • Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others • Glenmark Life Sciences for manufacturing and marketing APIs • Innovation new company (ICHNOS) to focus on discovery and development of novel, first‐in‐class treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs.


Maintain HOLD as we await EBITDA margin sustainability besides persisting US base business pressure amid regulatory hurdles at Monroe facility. We value Glenmark at Rs440 based on SOTP valuation.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Glenmark Pharmaceuticals - 160822 - ic

Broker Research
first published: Aug 17, 2022 03:19 pm
ISO 27001 - BSI Assurance Mark